Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00400803 · ClinicalTrials.gov registry record · Phase 2
Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00400803 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 38 participants.
The verdict
NCT00400803, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether treatment with carboplatin and gemcitabine combined with bevacizumab every two weeks will provide increased survival.
Interventions
- DRUG Gemcitabine, Carboplatin, Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2007-03 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00400803
The ClinicalTrials.gov registry entry for NCT00400803 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine, Carboplatin, Bevacizumab is the first listed.
NCT00400803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00400803 about?
NCT00400803 is a clinical study titled "Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer". The purpose of this study is to determine whether treatment with carboplatin and gemcitabine combined with bevacizumab every two weeks will provide increased survival.
What is the current status of trial NCT00400803?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2007-03. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00400803?
The interventions under investigation include: Gemcitabine, Carboplatin, Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00400803?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.